Jeffrey O. Boily
Chief Executive Officer & Chairman ProteaPex Therapeutics
Jeff Boily is a serial entrepreneur and investor with over 30 years of global life sciences experience. Jeff's emerging company and fund raising experience includes start-ups, growth stage and turnaround in pharmaceuticals, biotechnology, drug delivery, medical devices, and clinical informatics. He gained large company executive experience at Abbott, Rogers and Wyeth including Fort Dodge Animal Health. He has led IPO efforts, raised capital in the U.S. and Europe, and negotiated out-licensing and in-licensing agreements, joint ventures, divestitures and acquisitions in Japan, Europe, and North America. Most recently he was President and CEO of the Center for Animal Health Innovation, an animal health industry led organization providing proof of concept funding to accelerate the development of breakthrough products. Prior to this, he was CEO of BioWizard, a VC funded research and information firm for biomedical scientists. From 2002-2006 he was President and CEO of Rogers Medical Intelligence Solutions. The firm provided global R&D intelligence analysis and services to the top 50 global pharmaceutical and biotech companies. Previous experience includes Corporate Director and Global Managing Director of Scotia Holdings plc, a public UK biotechnology firm.
Jeff serves on various boards of for profit and not-for-profit organizations. He received his B.S. in biology from the U.of Ottawa and his M.B.A. from the John Molson School of Business, Concordia U., Montréal.
Marina D'Angelo, PhD
Chief Science Officer ProteaPex Therapeutics
Marina D’Angelo, PhD has over 25 years of experience in cell differentiation and cartilage biology. The major emphasis of her research endeavors has been chondrocyte biology. Over the last 20 years she has studied the role of growth factors and enzymes in normal chondrocyte differentiation and the disease pathway, osteoarthritis. She has held a faculty appointment at several major institutions in the Philadelphia area, including University of Pennsylvania, Temple University and Philadelphia College of Osteopathic Medicine. In addition to her role in ProteaPex Therapeutics, she is currently a Visiting Scholar in the Orthopedic Department at the School of Veterinary Medicine, University of Pennsylvania and a Professor in the Anatomy Department at Philadelphia College of Osteopathic Medicine.
Abdulhafez Selim, MD, PhD
Chief Medical Officer ProteaPex Therapeutics
Dr Selim has over 20 years of combined experience in bioinformatics, peptide design, cartilage and bone biology as well as pre-clinical and clinical research in medical device industry. He is co-inventor of the ECPF technology and has designed specific therapeutic peptides tailored to target pathological circuits. His design approach provides safer and effective alternative therapies to less specific inhibitors that are associated with unwanted side effects. Dr Selim trained at Harvard Medical school and has held several faculty positions both in the United States and abroad. He is currently adjunct faculty at Philadelphia College of Osteopathic Medicine in the Bio-Medical Sciences department.